

Hypoglycemic Effect of *Manniophyton Fulvum* Aqueous Root Extract on Streptozotocin-Induced Hyperglycemic Wistar Rats

Abstract

This study investigated the hypoglycemic effect of *M. fulvum* on streptozotocin (STZ) – induced hyperglycemia in Wistar rats. The oxidative damage in the blood, liver, pancreas and kidney cells, hepatic enzyme activities and lipid profile of the Wistar rats were also ascertained. Rats were exposed to STZ alone at 160 mg/kg body weight for one week to induced hyperglycemia before treatment with *M. fulvum* at 83 and 113 mg/kg for 28 consecutive days. Results showed significant elevation in the levels of blood glucose level, amylase activity, serum lipid profile and serum renal markers (total protein, urea and creatinine) in the hyperglycemic rats. Moreover, streptozotocin – induced rats showed significantly ($p < 0.05$) reduced antioxidant status (reduced levels of superoxide dismutase and catalase activities as well as decreased in reduced glutathione and increased level of malondialdehyde). *M. fulvum* was able to demonstrate marked hypoglycemic effect and ameliorate the above mentioned biochemical markers. Streptozotocin – induced rat's had significant histopathological damages found in the pancreas when compared with the control. The present study shows that *M. fulvum* possesses significant hypoglycemic, antihyperlipidemic and antioxidant effects in streptozotocin-induced hyperglycemic rats due to its ability to effectively reduced or ameliorate the increase in blood glucose levels, lipid profile and oxidative damages.

Keywords: *M. fulvum*, streptozotocin, hypoglycemic, hyperglycemic, antihyperlipidemic, antioxidant

28 **1. Introduction**

29 Diabetes mellitus developed due to metabolic imbalance which is non-physiological (Machha
30 et al., 2007). It is characterized by relative or absolute deficiencies in insulin secretion and/or
31 insulin action associated with chronic hyperglycemia and disturbances of carbohydrate, lipid
32 and protein metabolism (Duckworth, 2001). It is known worldwide (Elizza et al., 2009) that
33 diabetic mellitus affect about 7% of the adult populations (Babu et al., 2013) and it is
34 responsible for many deaths globally (Devi et al., 2012). The prevalence of diabetes cases is
35 increasing worldwide, especially in the developing countries (Shaw et al., 2010). Diabetes
36 mellitus is known to cause hyperglycemia that may result in the damage to the eyes, kidneys,
37 blood vessels, nerves and may adversely affect physical, social and psychological well-being
38 of an individual. Some symptoms associated with diabetes mellitus are blurring of vision,
39 weight loss, polyuria, polyphagia and polydipsia. Other serious symptoms of hyperglycemia
40 include non – hyperosmolar coma and ketoacidosis if left untreated (Devi et al. 2012).

41 Researchers all over the world are currently working on replacing synthetic anti-diabetic
42 drugs with natural antioxidants from plant materials found in our environment. This may be
43 as a results of new knowledge that diabetes mellitus is associated with the increased free
44 radical's formation and decreased antioxidant potential (Naziroğlu and Butterworth, 2005).
45 Research work have also shown that plants contain a large variety of substances that possess
46 antioxidant properties (Chanwitheesuk et al., 2005; Bacanli et al., 2017; Adedara et al.,
47 2017). This may lead to the formation of advanced glycated end products (AGEs) and other
48 diabetic complications associated with oxidative stress (Rahimi et al., 2005).

49 *M. fulvum* is one of the important herbs among the common people and local traditional
50 medicine practitioners in the region (Agbaire et al., 2013). It belongs to the family
51 euphorbiacea (Ojieh et al., 2013). In African traditional medicine the root, stem, bark and leaf
52 are credited with analgesic properties, and are used to treat diarrhea, stomach ache, cough,

53 bronchitis, oxidative stress and inflammation (Nia et al., 2005). The red stem sap is credited
54 with hemostatic properties, while the leaf sap is used against ear problems (Nia et al., 2005).
55 It is also known as a good treatment option for dysentery and dysmenorrhea (Bouquet et al.,
56 1969; Bouquet et al., 1974). The leaf of *M. fulvum* is credited with antioxidant and
57 antidiarrheal properties (Ezeigbo et al., 2010; Ojieh et al., 2013).
58 In the present study, the hypoglycemic effect of *M. fulvum* on streptozotocin – induced
59 hyperglycemia, oxidative damage in the blood, liver and kidney cells, hepatic enzyme
60 activities and lipid profile of Wistar rats were evaluated. To evaluate the oxidative damages,
61 the markers such as SOD, CAT activities as well as GSH and MDA levels; hepatic enzymes
62 AST, ALT and ALP activities; serum lipid profile such as HDL – C, LDL – C, total
63 cholesterol, triglyceride were determined to investigated the effect of *M. fulvum* on
64 streptozotocin – induced rats.

65

66 **2. Materials and Methods**

67 **2.1. Chemicals**

68 Streptozotocin, reduced glutathione, bovine serum albumin, glutathione, epinephrine, 5',5'-
69 dithio-bis-2-nitrobenzoic acid (DNTB), bovine serum albumin (BSA), trichloroacetic acid
70 (TCA), thiobarbituric acid (TBA) and hydrogen peroxide were obtained from Sigma-Aldrich
71 Chemical (St. Louis, MO). Sulfosalicylic acid, di-sodium hydrogen phosphate, sodium di-
72 hydrogen phosphate, and sodium hydroxide were purchased from E. Merck Limited. Total
73 cholesterol, triglycerides, low density lipoprotein (LDL-C), high density lipoprotein (HDL-C)
74 cholesterol levels, aspartate amino transferase, alanine amino transferase, alkaline
75 phosphatase, bilirubin (total and direct), creatinine, urea, and total proteins were estimated
76 from the serum using RANDOX kits. All other reagents were of highest analytical grade and
77 were purchased from the British Drug Houses (Poole, Dorset, UK).

78 **2.2. Animal Husbandry**

79 Fifty adult male Wistar rats (8 weeks old; 130 – 150g) obtained from the Department of
80 Biochemistry, Faculty of Science, University of Port Harcourt, Rivers State, Nigeria were
81 used for the present study. The animals were housed in plastic cages placed in a well-
82 ventilated vivarium and subjected to natural photoperiod of 12-h light:12-h dark cycle. They
83 were fed with rat chow and given drinking water ad libitum for two weeks before the
84 commencement of the experiment. All the animals received humane care according to the
85 conditions stated in the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the
86 National Academy of Science (NAS) and published by the National Institute of Health. The
87 experimental protocols were performed after approval by the University of Port Harcourt
88 Ethical Committee.

89

90 **2.3. Experimental Design**

91 **2.3.1. Streptozotocin-induced Hyperglycemia Model**

92 Wistar rats were kept in fasting condition for 12 h, thereafter hyperglycemia was induced by
93 intraperitoneal injection of STZ at 60 mg/kg in freshly prepared PBS, in 0.01 M citrate buffer
94 with a pH of 4.3. (Cumaoglu et al., 2011; Sabahi et al., 2016). After one week, blood samples
95 were obtained by tail prick, and hyperglycemia was confirmed by fasting (8 hours) blood
96 glucose value of 250 mg/dL higher using glucometer (Plusmed).

97 **2.4. Animals Treatment**

98 The rats were randomly divided to five groups of 8 rats each as follows:

99 **Group I (Control):** Rats received normal drinking water and feed for 35 consecutive days.

100 **Group II (MF):** Rats were orally treated with *M. fulvum* (MF) at 113 mg/kg body weight,
101 water and feed.

Group III (STZ): Rats were orally treated with streptozotocin (STZ) alone at a dose of 60 mg/kg body weight, water and feed.

Group IV (STZ + MF 1): Rats were orally co-administered with streptozotocin and *M. fulvum* at 85 mg/kg body weight, water and feed.

Group V (STZ + MF 2): Rats were orally co-administered with streptozotocin and *M. fulvum* at 113 mg/kg body weight, water and feed.

The doses of STZ (60 mg/kg) and MF (85 and 113 mg/kg) used in the present study were chosen based on the results from the pilot study in our laboratory.

2.5. Tissues Sampling

After the induction of diabetes and twenty-four hours after the 28 days' treatment, the final body weight of each rats were recorded. Blood samples were collected and kept in heparin containing tubes prior to the animal sacrifice by cervical dislocation. The collected blood samples were centrifuged at 3000 g for 10 min to obtain the plasma, which were thereafter stored frozen at -20°C before the biochemical assays. The pancreatic tissues were excised, weighed and processed for histological analyses after being washed with ice-cold phosphate-buffered saline.

2.6. Biochemical Assays

The plasma glucose concentration was determined using the One Touch™ glucose strips and glucometer. The serum activities of AST, ALP, ALT and amylase was determined using RANDOX test kits protocol (Randox laboratories, Crumlin, England). Serum levels of conjugated bilirubin, unconjugated bilirubin, total bilirubin, HL – Cholesterol, LL – Cholesterol, total cholesterol, triglyceride, creatinine, urea was also determined using RANDOX test kits protocol (Randox laboratories, Crumlin, England).

2.7. Oxidative Stress Assays

Reduced glutathione (GSH) was estimated by the method of Ellmans (Ellman, 1959). Malondialdehyde (MAD) was determined according to the method described by Ohkawa et al. (1979). Catalase was estimated according to the method of Sinha (1972) and superoxide dismutase (SOD) was estimated according to the method of Marklund and Marklund, 1974.

2.8. Histological Examination

The pancreas collected from 3 rats were fixed in 10% formalin – saline (PBS) solution for twenty – eight (28) at 4⁰C overnight and before embedded in paraffin the following day according to the method of Baker and Silverton, (1998). In brief, the fixed pancreas tissues were dehydrated in graded series of alcohol concentrations, cleared by xylene, impregnated in molten paraffin wax and embedded in paraffin wax. The embedded tissues were subsequently cut to produce 5-µm sections using a microtome, fixed on the slides, and stained with hematoxylin and eosin (H&E). Finally, the slides were viewed using the light microscope and histopathological changes were observed and recorded at X 200 magnification.

2.9. Statistical analysis

Statistical analyses were carried out using one-way analysis of variance (ANOVA) to compare the experimental groups followed by Bonferroni's post-hoc test using GRAPHPAD PRISM 5 software (Version 4; GraphPad Software, La Jolla, California, USA). Values of $p < 0.05$ were considered significant.

3. Results

3.1. Effect of *M. fulvum* aqueous root extract on fasting blood glucose level of streptozotocin-induced Hyperglycemic Wistar rats

The effects of *M. fulvum* on fasting blood glucose level in streptozotocin-induced hyperglycemic rats are presented in **Table 1**. There was no significant ($p \leq 0.05$) difference

in the blood glucose level before hyperglycemia induction. However, there was significant ($p \leq 0.05$) difference in in fasting blood glucose level in STZ alone, STZ + MF 1 and STZ + MF 2 groups when compared with the control. Furthermore, there was significant ($p \leq 0.05$) difference in fasting blood glucose level in STZ alone group when compared with the control. *M. fulvum* treatment significantly ($p \leq 0.05$) reduced fasting blood glucose level in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups. There was also significant ($p \leq 0.05$) difference in fasting blood glucose level in STZ + MF 1 and STZ + MF 2 groups when compared with the STZ alone group.

Table 1. Effect of *M. fulvum* aqueous root extract on fasting blood glucose level (mmol/L) of streptozotocin-induced diabetic Wistar rats


Groups	Before Induction	After Induction	After Treatment
Control	4.84±1.34	5.19±1.11	5.16±1.45
MF alone	5.05±1.21	5.07±1.46	4.84±1.34
STZ alone	4.63±1.53	7.25±1.19 ^a	8.87±1.12 ^a
STZ + MF 1	4.84±1.34	7.14±1.09 ^{a,b}	6.58±1.39 ^{a,b}
STZ + MF 2	4.96±1.22	7.27±1.17 ^{a,b}	5.83±1.16 ^b

STZ = streptozotocin, MF = *M. fulvum*. The data are expressed as Mean ± SD; (n = 5). “a” significantly different from the control at $p \leq 0.05$, while “b” significantly different from the STZ alone at $p \leq 0.05$.

3.2. Effect of *M. fulvum* aqueous root extract on amylase activity of streptozotocin-induced diabetic Wistar rats

The effects of *M. fulvum* on amylase activity in streptozotocin-induced diabetic rats are presented in **Figure 1**. There was significant ($p \leq 0.05$) difference in amylase activity in STZ alone when compared to the control. Also, STZ + MF 1 and STZ + MF 2 groups were significantly ($p \leq 0.05$) different when compared with the STZ alone group.

171



172

173 **Figure 1:** The effect of *M. fulvum* on streptozotocin – induced Wistar rats on amylase activity
 174 in serum of rat. streptozotocin, STZ; *M. fulvum*, MF; STZ (160 mg/kg body weight); MF 1,
 175 (83 mg/kg body weight); MF 2, (113 mg/kg body weight). The data are expressed as mean \pm
 176 S.D. for 5 rats per group. a: Values differ significantly from control ($p \leq 0.05$). b: Values
 177 differ significantly from STZ alone at $p \leq 0.05$.

178 3.3. Effect of *M. fulvum* aqueous root extract on AST, ALP and ALT activities of 179 streptozotocin-induced diabetic Wistar rats

180 The effects of *M. fulvum* on liver function markers (AST, ALP and ALT activities) in
 181 streptozotocin-induced diabetic rats are presented in **Figure 2**. There was significant ($p \leq$
 182 0.05) difference in AST, ALP and ALT activities in STZ alone when compared to the
 183 control. Treatment with *M. fulvum* significantly ($p \leq 0.05$) decreased AST, ALP and ALT
 184 activities in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups when compared to
 185 the STZ alone group.




Figure 2: The effect of *M. fulvum* on streptozotocin – induced Wistar rats on AST, ALT and ALP activity in serum of rat. streptozotocin, STZ; *M. fulvum*, MF; STZ (160 mg/kg body weight); MF 1, (83 mg/kg body weight); MF 2, (113 mg/kg body weight). The data are expressed as mean ± S.D. for 5 rats per group. a: Values differ significantly from control ($p \leq 0.05$). b: Values differ significantly from STZ alone at $p \leq 0.05$.

3.4. Effect of *M. fulvum* aqueous root extract on conjugated bilirubin, unconjugated bilirubin and total bilirubin levels of streptozotocin-induced diabetic Wistar rats

The effects of *M. fulvum* on conjugated bilirubin, unconjugated bilirubin and total bilirubin levels in streptozotocin-induced diabetic rats are presented in **Figure 3**. There was significant ($p \leq 0.05$) difference in conjugated bilirubin, unconjugated bilirubin and total bilirubin levels in STZ alone when compared to the control. Moreover, treatment with *M. fulvum* for 28 days significantly ($p \leq 0.05$) decreased the levels of conjugated bilirubin, unconjugated bilirubin and total bilirubin in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups when compared to the STZ alone group.





Figure 3: The effect of *M. fulvum* on streptozotocin – induced Wistar rats on conjugated bilirubin, unconjugated bilirubin and total bilirubin levels in serum of rat. streptozotocin, STZ; *M. fulvum*, MF; STZ (160 mg/kg body weight); MF 1, (83 mg/kg body weight); MF 2, (113 mg/kg body weight). The data are expressed as mean \pm S.D. for 5 rats per group. a: Values differ significantly from control ($p \leq 0.05$). b: Values differ significantly from STZ alone at $p \leq 0.05$.

3.5. Effect of *M. fulvum* aqueous root extract on cholesterol levels of streptozotocin-induced hyperglycemic Wistar rats

The effects of *M. fulvum* on HDL – cholesterol, LDL – cholesterol, total cholesterol and triglyceride levels in streptozotocin-induced diabetic rats are presented in **Figure 4**. There was significant ($p \leq 0.05$) difference in HDL – cholesterol, LDL – cholesterol, total cholesterol and triglyceride levels in STZ alone when compared to the control. But after treatment with *M. fulvum* for 28 days significantly ($p \leq 0.05$) decreased the levels of HDL – cholesterol, LDL – cholesterol, total cholesterol and triglyceride in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups when compared to the STZ alone. Furthermore, there was also significantly ($p \leq 0.05$) difference between STZ + MF 1 and STZ + MF 2 groups when compared to the control group.

221



222

223 **Figure 4:** The effect of *M. fulvum* on streptozotocin – induced Wistar rats on HDL – C, LDL
 224 – C, total cholesterol and triglyceride levels in serum of rat. streptozotocin, STZ; *M. fulvum*,
 225 MF; STZ (160 mg/kg body weight); MF 1, (83 mg/kg body weight); MF 2, (113 mg/kg body
 226 weight). The data are expressed as mean \pm S.D. for 5 rats per group. a: Values differ
 227 significantly from control ($p \leq 0.05$). b: Values differ significantly from STZ alone at $p \leq$
 228 0.05.

229 3.6. Effect of *M. fulvum* aqueous root extract on urea and creatinine levels of 230 streptozotocin-induced diabetic Wistar rats

231 The effects of *M. fulvum* on urea and creatinine levels in streptozotocin-induced
 232 hyperglycemic rats are presented in **Figure 5**. There was significant ($p \leq 0.05$) difference in
 233 urea and creatinine levels in STZ alone when compared to the control. However, treatment
 234 with *M. fulvum* for 28 days significantly ($p \leq 0.05$) decreased the levels of urea and
 235 creatinine levels in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups when
 236 compared to the STZ alone.

237




Figure 5: The effect of *M. fulvum* on streptozotocin – induced Wistar rats on urea and creatinine levels in serum of rat. streptozotocin, STZ; *M. fulvum*, MF; STZ (160 mg/kg body weight); MF 1, (83 mg/kg body weight); MF 2, (113 mg/kg body weight). The data are expressed as mean \pm S.D. for 5 rats per group. a: Values differ significantly from control ($p \leq 0.05$). b: Values differ significantly from STZ alone at $p \leq 0.05$.

3.7. Effect of *M. fulvum* aqueous root extract on cholesterol levels of streptozotocin-induced hyperglycemic Wistar rats

The effects of *M. fulvum* on SOD and CAT activities as well as GSH and MDA levels in streptozotocin-induced hyperglycemic rats are presented in **Figure 6**. There was significant ($p \leq 0.05$) difference in SOD and CAT activities as well as GSH and MDA levels in STZ alone when compared to the control. However, after 28 days' treatment with *M. fulvum* significantly ($p \leq 0.05$) increased SOD and CAT activities as well as GSH and MDA levels in the treated group i.e. STZ + MF 1 and STZ + MF 2 groups when compared to the STZ alone.




Figure 6: The effect of *M. fulvum* on streptozotocin – induced Wistar rats on SOD, CAT activities as well as GSH and M D A levels in serum of rat. streptozotocin, STZ; *M. fulvum*, MF; STZ (160 mg/kg body weight); MF 1, (83 mg/kg body weight); MF 2, (113 mg/kg body weight). The data are expressed as mean \pm S.D. for 5 rats per group. a: Values differ significantly from control ($p \leq 0.05$). b: Values differ significantly from STZ alone at $p \leq 0.05$.

3.8. The Effect of *M. fulvum* on Streptozotocin – induced damages in the Pancreas

The Effect of *M. fulvum* on streptozotocin – induced damages in the pancreas is shown in **Figure 7**. Streptozotocin – induced rat's had significant reduction in islet cell mass when compared to the control. However, after treatment with *M. fulvum* i.e. STZ + MF 1 an STZ + MF 2 groups significant increased the islet cell mass when compared with the STZ control group.




Figure 7: Representative histopathological sections of the pancreas from the experimental rats. The pancreas of rats from the control (A) and *M. fulvum* alone (B) groups showing normal morphology. The pancreas of rats administered with streptozotocin alone (C) showing marked pancreatic degeneration. However, the pancreas of rats co-administered with *M. fulvum* at 85 and 113 mg/kg, respectively (D, E) showing normal pancreas and it appeared structurally normal and similar to the control. Magnification of $\times 250$.

Discussion

In the present study, we investigated the influence of *M. fulvum* against streptozotocin – induced hyperglycemia and its complications in Wistar albino rats. Streptozotocin – induced hyperglycemia has been described by many scientist as a notable experimental model to diabetes mellitus (Junod et al., 1969; Bacanli et al., 2017). Streptozotocin is known to causes massive reduction in insulin release as a result of the destruction of the β -cells of the islets of Langerhans, thereby resulting in the induction of hyperglycemia experimental model (Schein et al., 1973). Free radicals are generated disproportionately in diabetes experimental model (Bacanli et al., 2017). This may result in the simultaneous decline of antioxidant defense systems which may lead to damage of cellular organelles and enzymes, increased lipid peroxidation, and the subsequent development of insulin resistance. All these complications may promote the development of complications of diabetes mellitus (Maritim et al., 2003).

Several local herbs are being used by the population as alternative therapy for the treatment of diabetes. Most of these herbs have not been subjected to scientific scrutiny to determine their potency. In the present study, we examine the antidiabetic influence of *M. fulvum* on streptozotocin – induced Wistar rats. Streptozotocin – induced significant increase in fasting blood glucose but *M. fulvum* lower the fasting blood glucose level to normal in streptozotocin – induced Wistar rats.

The pancreas produces amylase which hydrolyses dietary starch into disaccharides and trisaccharides. High concentration of serum level of amylase indicates damage of pancreas. In the present study, streptozotocin – induced increased significant increase in amylase activity.

299 This implies that streptozotocin may be the cause of the high pancreatic damage as also
300 suggested by previous researches (Kronke *et al.*, 1995; O'Brien *et al.*, 1996). However, *M*
301 *fulvum* restored serum amylase activity to normal, indicating that *M. fulvum* ameliorate
302 pancreatic damage induced by streptozotocin.

303 Liver function enzymes are important markers in diabetic diagnosis and management as it
304 helps to determine the extent of liver damage. In the present study, there was significant
305 increase in the liver function markers in the streptozotocin exposed group. However, *M.*
306 *fulvum* significantly reduced the liver functions enzymes in the treated groups when
307 compared with the control. The liver plays an important role in glycolysis and
308 gluconeogenesis (Hiroshi *et al.*, 1989), because it is an insulin dependent tissue, which plays
309 a pivotal role in lipid homeostasis and glucose. In diabetic condition, the liver is severely
310 affected (Gupta *et al.*, 1999). In the present study, AST, ALT and ALP enzymes were
311 significantly when compared to the control (Monami *et al.*, 2008). It has been observed that
312 AST, ALT an ALP enzymes activities in serum of 28 type 1 diabetic patients have elevated
313 enzymes activities (Arkkila *et al.*, 2001). The elevated conjugated and unconjugated bilirubin
314 levels along with increased in total bilirubin observed in streptozotocin – induced rats may be
315 an indication of hepatobiliary damages. However, *M. fulvum* was able to ameliorate the in
316 increased in conjugated and unconjugated and total bilirubin.

317 *M. fulvum* treatment reduced serum triglycerides, low-density lipoprotein cholesterol (LDL-c)
318 and fasting blood glucose levels and glucose tolerance, and increased serum high density
319 lipoprotein cholesterol (HDL-c), total cholesterol, and triglyceride. This lipid profile is used
320 to measure hyperlipidaemia which is one of the complications of diabetes. In the present
321 study, there was significant ($p < 0.05$) increase in HDL-C, LDL-C, total cholesterol, and
322 triglyceride in the streptozotocin – induced group (**Figs. 4**). However, *M. fulvum* was
323 observed to reduce the elevated levels of the serum lipid profile. The elevation of cholesterol

in the diabetic control group support the fact that in severe insulin deficiency, there is accelerated lipolysis which result in elevated plasma triacylglycerol level. In the diabetic state, as shown by the elevated fasting blood glucose level of same group. *M. fulvum* being a rich protein supplement and antioxidant, it might have antihyperlipidemic activities, thereby resulting in the reduction the rise in serum cholesterol.

Urea and creatinine are nitrogenous end product of metabolism. Urea is the primary metabolite derived from protein turnover while creatinine is the product of muscle catabolism. Elevation of urea and creatinine marks renal failure. Since renal failure is one of the complications of diabetes, the serum levels of urea and creatinine was investigated. Streptozotocin – induced rats show alterations in renal functional markers. There was significant ($p < 0.05$) increase in the renal functional markers (urea and creatinine) of the streptozotocin – induced group (**Figs. 5**). Similar alternation has been reported in several studies (Eidi et al. 2006; Erejuwa et al. 2011). However, *M. fulvum* was observed to reduce the elevated levels of renal functional markers, which has also been reported in several studies (Erejuwa et al. 2011; Devi et al. 2012).

The imbalance in pro-oxidants and antioxidants which can result in macromolecular damage (lipid peroxidation) and disruption of redox signalling leads to oxidative stress. The antioxidant enzymes (SOD, CAT and GSH) protect major macromolecules in cell from oxidative damage caused by reactive oxygen species (ROS). SOD catalyses the removal of superoxide radicals to generate hydrogen peroxide (H_2O_2) which in turn is decomposed by catalase (CAT) producing molecular oxygen and water which are not toxic. GSH plays a central role in detoxification and protection against the generation of free radicals thereby maintaining the integrity of cells. In the present study, the streptozotocin – induced oxidative stress (**Fig. 6**). However, *M. fulvum* significantly increased the plasma activities of superoxide dismutase and catalase, and concentration of reduced glutathione, and reduced significantly the

concentration of malondialdehyde. This antioxidant activity may be credited to quercetin present in the aqueous root extract of *M. fulvum*, hence, supporting the previous findings (Boots *et al.*, 2008; Bando *et al.*, 2010). Streptozotocin – induced rat's had significant histopathological damages found in the pancreas when compared with the control. However, *M. fulvum* treatment was able to minimize the pancreatic tissue damages.

Conclusion

The present study shows that *M. fulvum* possesses significant hypoglycemic, antihyperlipidemic and antioxidant effects in streptozotocin-induced hyperglycemic rats due to its ability to effectively reduced or ameliorate the increase in blood glucose levels, lipid profile and oxidative damages.

References

- Adedara, I.A., Ego V.C., Subair I.T., Oyediran O., Farombi, E.O. (2017). Quercetin improves neurobehavioral performance through restoration of brain antioxidant status and acetylcholinesterase activity in manganese-treated rats. *Neurochemical Research*, 42, 1219–1229
- Agbaire, P.O., Emudainohwo, J.O., and Peretiemo-Claire, B. O. (2013). Phytochemical screening and toxicity studies on the leaves of *Manniophyton fulvum*. *International Journal of plant, Animal and Environmental Sciences*. 3(1)1-6.
- Arkkila, P.E., Koskinen, P.J., Kantola, I.M., Rönnemaa, T., Seppänen, E., Viikari, J.S. (2001). Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. *Diabetes Res. Clin. Pr.* 52, 113-118.
- Babu, P.V.A., Liu, D., Gilbert, E.R. (2013). Recent advances in understanding the anti-diabetic actions of dietary flavonoids. *J Nutr Biochem* 24:1777–1789.
- Bacanli, M., Gül Anlar, H., Aydin, S., Çal, Tuğü., Ari, N., Bucurgat, Üü.Üğ., Başaran, A.A., Başaran, Nurş. (2017). D-limonene ameliorates diabetes and its complications in

378 streptozotocin-induced diabetic rats, Food and Chemical Toxicology, doi:
379 10.1016/j.fct.2017.09.020.

380 Bando, N., Muraki, N., Murota, K., Terao, J., and Yamanishi, R. (2010). Ingested quercetin
381 but not rutin increases accumulation of hepatic beta-carotene in BALB/c mice. Molecular
382 Nutrition and Food Research, 54(Suppl 2): S261-S267.

383

384 Boots, A.W., Haenen, G.R. and Bast, A. (2008). Health effects of quercetin: from antioxidant
385 to nutraceutical. European Journal of Pharmacology, 582(2-3): 325-337

386

387 Bouquet, A.J. (1969). Natural products as an alternative remedy. (24th ed.). Kew: Royal
388 Botanic Gardens.

389

390 Bouquet, A., Debray, M. (1974). Plants medicinales dela C'ote d'Ivoire. Vol. 32. Paris:
391 Travaux et Documents De' I O.R.S.T.O.M.

392

393 Chanwitheesuk, A., Teerawutgulrag, A., Rakariyatham, N., (2005). Screening of antioxidant
394 activity and antioxidant compounds of some edible plants of Thailand. Food Chem. 92, 491-
395 497.

396

397 Cumaoglu, A., Ozansoy, G., Irat, A.M., Aricioğlu, A., Karasu, Ç., Ari, N. (2011). Effect of
398 long term, non-cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain
399 and peripheral tissues of streptozotocin-diabetic rats. Eur. J. Pharmacol. 654, 80-85.

400

401 Devi, Y.A., Vrushabendra, Swamy B.M., Vishwanath, Swamy K.M., Ramu Ravi, R. (2012).
402 Antidiabetic activity of Echinochloa crusgalli (L.) P. Beauv grains extract in alloxan induced
403 diabetic rats. Res J Pharmaceut Biol Chem Sci 3:1257

404

405 Duckworth, W.C., (2001). Hyperglycemia and cardiovascular disease. Curr. Ather. Rep. 3,
406 383- 391.

407

408 Eidi, A., Eidi, M., Esmaeili, E. (2006). Antidiabetic effect of garlic (*Allium sativum* L.) in
409 normal and streptozotocin-induced diabetic rats. Phytomedicine 13:624–629.

410

- 411 Eliza, J., Daisy, P., Ignacimuthu, S., Duraipandiyan, V. (2009). Antidiabetic and
412 antilipidemic effect of eremanthin from *Costus speciosus* (Koen.)Sm., in STZ-induced
413 diabetic rats. *Chem Biol Interact* 182:67–72.
- 414 Ellman, G.L. (1959). Tissue sulfhydryl groups. *Archives of Biochemistry and Biophysics*, 82:
415 70 77.
- 416
- 417 Erejuwa, O.O., Sulaiman, S.A., Wahab, M.S. (2011) Effect of glibenclamide alone versus
418 glibenclamide and honey on oxidative stress in pancreas of streptozotocin-induced diabetic
419 rats. *Int J Appl Res Nat Prod* 4:1–10
- 420
- 421 Ezeigbo, I.I., Ejike, C.E.C.C., and Ezeja, M. I., Eneh, O. (2010). Antioxidant and
422 Antidiarrheal activities of *Manniophyton fulvum* leaf extract in mice. *Continental Journal of*
423 *Animal and Veterinary Research*, 2:41-47.
- 424
- 425 Gupta, D., Raju, J., Baquer, N.Z. (1999). Change in the lipid profile, lipogenic and related
426 enzymes in the livers of experimental diabetic rats: effect of insulin and vanadate. *Diabetes*
427 *Res. Clin. Pr.* 46, 1-7.
- 428
- 429 Hiroshi, H., Masako, K., Yutaka, S., Chohachi, K., (1989). Mechanisms of hypoglycemic
430 activity of aconitan A, a glycan from *Aconitum carmichaeli* roots. *J. Ethnopharmacol.* 25,
431 295-304.
- 432
- 433 Junod, A., Lambert, A.E., Stauffacher, W., Renold, A.E., (1969). Diabetogenic action of
434 streptozotocin: relationship of dose to metabolic response. *J. Clin. Invest.* 48, 2129.
- 435
- 436 Kronke, K.D., Feshel, K., Sommer, A., Rodriguez, M.L., Koibbachofen, (1995). Nitric
437 Oxide generation during cellular metabolism of the diabetogenic N-methyl-N-
438 nitroso-urea, streptozotocin contribute to islet cell DNA damage. *Biological Chemistry*,
439 376:179-185.
- 440
- 441 Maritim, A., Sanders, A., Watkins, J., (2003). Diabetes, oxidative stress, and antioxidants: a
442 review. *J. Biochem. Mol. Toxicol.* 17, 24-38.

- 443 Marklund, S.L. and Marklund, G. (1974). Involvement of superoxide anion radical in the auto
444 oxidation of pyrogallol and convenient assay for superoxide dismutase. *European*
445 *Journal of Biochemistry*, 47: 469.
- 446
- 447 Monami, M., Bardini, G., Lamanna, C., Pala, L., Cresci, B., Francesconi, P., Buiatti, E.,
448 Rotella, C.M., Mannucci, E., (2008). Liver enzymes and risk of diabetes and cardiovascular
449 disease: results of the Firenze Bagno a Ripoli (FIBAR) study. *Metabolism* 57, 387-392.
- 450
- 451 Naziroğlu, M., Butterworth, P.J., (2005). Protective effects of moderate exercise with dietary
452 vitamin C and E on blood antioxidative defense mechanism in rats with
453 streptozotocin-induced diabetes. *Can. J. Appl. Physiol.* 30, 172-185.
- 454
- 455 Nia, R., Paper, D. H., Franz, G., Essien, E. E., Muganza, M., and Hohmann, G. (2005). Anti-
456 oxidant and anti-inflammatory activity of *Manniophyton fulvum*. *Acta Horticulturae*, 678:
457 97-101.
- 458 O'Brien, B., Quigg, C., Leong, T. (2005). Severe cyanide toxicity from vitamin supplements.
459 *European Journal of Emergency Medicine*, 12(5): 257-258.
- 460
- 461 Ohkawa, H., Ohishi, N., Yagi, K. (1979). Assay for Lipid Peroxidation in animal tissues by
462 thiobarbituric acid reaction. *Analytical Biochemistry*, 95:351.
- 463 Ojeh, E.A., Adegbor, C.E., Ovuakporaye, I.S., Ewhre, O L. (2013). Preliminary
464 Phytochemical screening and antidiarrheal properties of *Manniophyton fulvum*. *Journal of*
465 *Dental and Medical Science*, 10 (2); 46-52.
- 466
- 467 Rahimi, R., Nikfar, S., Larijani, B., Abdollahi, M., (2005). A review on the role of
468 antioxidants in the management of diabetes and its complications. *Biomed. Pharmacother.* 59,
469 365-373. Ramesh, B., Pugalandi, K., 2006. Antioxidant role of umbelliferone in STZ-diabetic
470 rats. *Life Sci.* 79, 306-310.
- 471
- 472 Sabahi, Z., Khoshnood-Mansoorkhani, M.J., Namadi, S.R., Moein, M., (2016). Antidiabetic
473 and Synergistic Effects Study of Anthocyanin Fraction from *Berberis integerrima* Fruit on
474 Streptozotocin-Induced Diabetic Rats Model. *Trends in Pharm. Sci.* 2, 43-50.

475

476 Schein, P.S., Cooney, D.A., McMenamin, M.G., Anderson, T., (1973). Streptozotocin
477 diabetes—further studies on the mechanism of depression of nicotinamide adenine
478 dinucleotide concentrations in mouse pancreatic islets and liver. *Biochem. Pharmacol.* 22,
479 2625-2631.

480

481 Shaw, J.E., Sicree, R.A., Zimmet, P.Z., (2010). Global estimates of the prevalence of diabetes
482 for 2010 and 2030. *Diabetes Res. Clin. Pr.* 87, 4-14.

483

484 Sinha, A.K. (1972). Colorimetric assay of catalase. *Analytical Biochemistry*, 47: 389-394.